Cite

    Abdelmoneim, A. et al. (n.d.). Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study. Diabetes, obesity & metabolism. 16 (1), pp. 22-29. [Online].